CytomX Therapeutics, Inc. Increase (Decrease) in Contract with Customer, Liability
CytomX Therapeutics, Inc. (CTMX) reported Increase (Decrease) in Contract with Customer, Liability of $26.22 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInContractWithCustomerLiability · last filed 2026-08-06
- CytomX Therapeutics, Inc. increase (decrease) in contract with customer, liability for the quarter ending 2026-06-30 was $35.84M.
- CytomX Therapeutics, Inc. increase (decrease) in contract with customer, liability for the quarter ending 2026-03-31 was -$9.61M.
- CytomX Therapeutics, Inc. increase (decrease) in contract with customer, liability for the quarter ending 2025-12-31 was $551.00K.
- CytomX Therapeutics, Inc. increase (decrease) in contract with customer, liability for the quarter ending 2025-09-30 was -$4.38M.
- CytomX Therapeutics, Inc. increase (decrease) in contract with customer, liability for fiscal 2025 was -$65.60M.
- CytomX Therapeutics, Inc. increase (decrease) in contract with customer, liability for fiscal 2024 was -$118.25M.
- CytomX Therapeutics, Inc. increase (decrease) in contract with customer, liability for fiscal 2023 was -$89.01M, a 637.34% decline from fiscal 2022.
- CytomX Therapeutics, Inc. increase (decrease) in contract with customer, liability for fiscal 2022 was $16.57M.
| Period end | Increase (Decrease) in Contract with Customer, Liability 3 month | Increase (Decrease) in Contract with Customer, Liability 3 month as first filed | Increase (Decrease) in Contract with Customer, Liability 6 month | Increase (Decrease) in Contract with Customer, Liability 6 month as first filed | Increase (Decrease) in Contract with Customer, Liability 9 month | Increase (Decrease) in Contract with Customer, Liability 9 month as first filed | Increase (Decrease) in Contract with Customer, Liability 12 month | Increase (Decrease) in Contract with Customer, Liability 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $35.84M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $26.22M 10-Q · filed 2026-08-06 | $26.77M derived: sum of 3 quarters · filed 2026-08-06 | $22.40M derived: sum of 4 quarters · filed 2026-08-06 | ||||
| 2026-03-31 | -$9.61M 10-Q · filed 2026-05-07 | -$9.06M derived: sum of 2 quarters · filed 2026-05-07 | -$13.44M derived: sum of 3 quarters · filed 2026-05-07 | -$30.59M derived: sum of 4 quarters · filed 2026-08-06 | ||||
| 2025-12-31 | $551.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-16 | -$3.82M derived: sum of 2 quarters · filed 2026-03-16 | -$20.97M derived: sum of 3 quarters · filed 2026-08-06 | -$65.60M 10-K · filed 2026-03-16 | ||||
| 2025-09-30 | -$4.38M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | -$21.52M derived: sum of 2 quarters · filed 2026-08-06 | -$66.15M 10-Q · filed 2025-11-06 | -$101.70M derived: sum of 4 quarters · filed 2026-08-06 | ||||
| 2025-06-30 | -$17.15M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | -$61.77M 10-Q · filed 2026-08-06 | -$97.33M derived: sum of 3 quarters · filed 2026-08-06 | -$128.19M derived: sum of 4 quarters · filed 2026-08-06 | ||||
| 2025-03-31 | -$44.62M 10-Q · filed 2026-05-07 | -$80.18M derived: sum of 2 quarters · filed 2026-05-07 | -$111.04M derived: sum of 3 quarters · filed 2026-05-07 | -$133.93M derived: sum of 4 quarters · filed 2026-05-07 | ||||
| 2024-12-31 | -$35.56M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-16 | -$66.41M derived: sum of 2 quarters · filed 2026-03-16 | -$89.31M derived: sum of 3 quarters · filed 2026-03-16 | -$118.25M 10-K · filed 2026-03-16 | ||||
| 2024-09-30 | -$30.86M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | -$53.75M derived: sum of 2 quarters · filed 2025-11-06 | -$82.70M 10-Q · filed 2025-11-06 | -$107.04M derived: sum of 4 quarters · filed 2025-11-06 | ||||
| 2024-06-30 | -$22.89M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | -$51.84M 10-Q · filed 2025-08-07 | -$76.18M derived: sum of 3 quarters · filed 2025-08-07 | -$100.68M derived: sum of 4 quarters · filed 2025-08-07 | ||||
| 2024-03-31 | -$28.94M 10-Q · filed 2025-05-12 | -$53.29M derived: sum of 2 quarters · filed 2025-05-12 | -$77.78M derived: sum of 3 quarters · filed 2025-05-12 | -$100.55M derived: sum of 4 quarters · filed 2025-05-12 | ||||
| 2023-12-31 | -$24.34M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-06 | -$48.84M derived: sum of 2 quarters · filed 2025-03-06 | -$71.60M derived: sum of 3 quarters · filed 2025-03-06 | -$89.01M 10-K · filed 2025-03-06 | ||||
| 2023-09-30 | -$24.50M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | -$47.26M derived: sum of 2 quarters · filed 2024-11-07 | -$64.67M 10-Q · filed 2024-11-07 | -$18.80M derived: sum of 4 quarters · filed 2024-11-07 | ||||
| 2023-06-30 | -$22.76M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | -$40.17M 10-Q · filed 2024-08-08 | $5.69M derived: sum of 3 quarters · filed 2024-08-08 | -$3.74M derived: sum of 4 quarters · filed 2024-08-08 | ||||
| 2023-03-31 | -$17.41M 10-Q · filed 2024-05-08 | $28.45M derived: sum of 2 quarters · filed 2024-05-08 | $19.02M derived: sum of 3 quarters · filed 2024-05-08 | $7.18M derived: sum of 4 quarters · filed 2024-05-08 | ||||
| 2022-12-31 | $45.86M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-11 | $36.43M derived: sum of 2 quarters · filed 2024-03-11 | $24.59M derived: sum of 3 quarters · filed 2024-03-11 | $16.57M 10-K · filed 2024-03-11 | ||||
| 2022-09-30 | -$9.44M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-07 | -$21.27M derived: sum of 2 quarters · filed 2023-11-07 | -$29.30M 10-Q · filed 2023-11-07 | -$48.48M 10-Q · filed 2022-11-08 | -$39.64M derived: sum of 4 quarters · filed 2023-11-07 | |||
| 2022-06-30 | -$11.84M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | -$19.86M 10-Q · filed 2023-08-08 | -$33.27M 10-Q · filed 2022-08-04 | -$30.21M derived: sum of 3 quarters · filed 2023-08-08 | -$38.51M derived: sum of 4 quarters · filed 2023-08-08 | |||
| 2022-03-31 | -$8.03M 10-Q · filed 2023-05-09 | -$16.12M 10-Q · filed 2022-05-05 | -$18.37M derived: sum of 2 quarters · filed 2023-05-09 | -$26.67M derived: sum of 3 quarters · filed 2023-05-09 | -$34.53M derived: sum of 4 quarters · filed 2023-05-09 | |||
| 2021-12-31 | -$10.34M derived: 10-K/A 12 month − 10-K/A 9 month · filed 2023-03-27 | -$18.64M derived: sum of 2 quarters · filed 2023-03-27 | -$26.51M derived: sum of 3 quarters · filed 2023-03-27 | -$33.95M 10-K/A · filed 2023-03-27 | -$66.21M 10-K · filed 2022-03-01 | |||
| 2021-09-30 | -$8.30M derived: 10-K/A 9 month − 10-K/A 6 month · filed 2023-03-27 | -$16.17M derived: sum of 2 quarters · filed 2023-03-27 | -$23.61M 10-K/A · filed 2023-03-27 | -$47.27M 10-Q · filed 2021-11-04 | -$30.19M derived: sum of 4 quarters · filed 2023-03-27 | |||
| 2021-06-30 | -$7.87M derived: 10-K/A 6 month − 10-K/A 3 month · filed 2023-03-27 | -$15.30M 10-K/A · filed 2023-03-27 | -$30.57M 10-Q · filed 2021-08-05 | -$21.89M derived: sum of 3 quarters · filed 2023-03-27 | -$28.81M derived: sum of 4 quarters · filed 2023-03-27 | |||
| 2021-03-31 | -$7.44M 10-K/A · filed 2023-03-27 | -$15.21M 10-Q · filed 2021-05-06 | -$14.02M derived: sum of 2 quarters · filed 2023-03-27 | -$20.95M derived: sum of 3 quarters · filed 2023-03-27 | -$27.73M derived: sum of 4 quarters · filed 2023-03-27 | |||
| 2020-12-31 | -$6.58M derived: 10-K/A 12 month − 10-K/A 9 month · filed 2023-03-27 | -$13.51M derived: sum of 2 quarters · filed 2023-03-27 | -$20.29M derived: sum of 3 quarters · filed 2023-03-27 | $62.83M 10-K/A · filed 2023-03-27 | $30.89M 10-K · filed 2021-02-24 | |||
| 2020-09-30 | -$6.93M derived: 10-K/A 9 month − 10-K/A 6 month · filed 2023-03-27 | -$13.71M derived: sum of 2 quarters · filed 2023-03-27 | $69.41M 10-K/A · filed 2023-03-27 | $46.77M 10-Q · filed 2020-11-05 | $91.43M derived: sum of 4 quarters · filed 2023-03-27 | |||
| 2020-06-30 | -$6.78M derived: 10-K/A 6 month − 10-K/A 3 month · filed 2023-03-27 | $76.33M 10-K/A · filed 2023-03-27 | $64.01M 10-Q · filed 2020-08-06 | $98.35M derived: sum of 3 quarters · filed 2023-03-27 | $87.65M derived: sum of 4 quarters · filed 2023-03-27 | |||
| 2020-03-31 | $83.11M 10-K/A · filed 2023-03-27 | $80.42M 10-Q · filed 2020-05-07 | $105.14M derived: sum of 2 quarters · filed 2023-03-27 | $94.43M derived: sum of 3 quarters · filed 2023-03-27 | $95.42M derived: sum of 4 quarters · filed 2023-03-27 | |||
| 2019-12-31 | $22.02M derived: 10-K/A 12 month − 10-Q 9 month · filed 2023-03-27 | $11.32M derived: sum of 2 quarters · filed 2023-03-27 | $12.31M derived: sum of 3 quarters · filed 2023-03-27 | -$17.15M 10-K/A · filed 2023-03-27 | -$47.74M 10-K · filed 2020-02-27 | |||
| 2019-09-30 | -$10.71M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-05 | -$9.71M derived: sum of 2 quarters · filed 2020-11-05 | -$39.17M 10-Q · filed 2020-11-05 | -$50.56M derived: sum of 4 quarters · filed 2021-02-24 | ||||
| 2019-06-30 | $991.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-06 | -$28.47M 10-Q · filed 2020-08-06 | -$39.85M derived: sum of 3 quarters · filed 2021-02-24 | -$52.32M derived: sum of 4 quarters · filed 2021-02-24 | ||||
| 2019-03-31 | -$29.46M 10-Q · filed 2020-05-07 | -$40.84M derived: sum of 2 quarters · filed 2021-02-24 | -$53.31M derived: sum of 3 quarters · filed 2021-02-24 | -$53.52M derived: sum of 4 quarters · filed 2021-02-24 | ||||
| 2018-12-31 | -$11.38M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-24 | -$23.85M derived: sum of 2 quarters · filed 2021-02-24 | -$24.06M derived: sum of 3 quarters · filed 2021-02-24 | -$38.20M 10-K · filed 2021-02-24 | ||||
| 2018-09-30 | -$12.47M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-07 | -$12.68M derived: sum of 2 quarters · filed 2019-11-07 | -$26.81M 10-Q · filed 2019-11-07 | |||||
| 2018-06-30 | -$213.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-07 | -$14.35M 10-Q · filed 2019-08-07 | ||||||
| 2018-03-31 | -$14.13M 10-Q · filed 2019-05-09 | |||||||
| 2017-12-31 | $189.91M 10-K · filed 2020-02-27 | |||||||
| 2016-12-31 | $43.32M 10-K · filed 2019-02-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| Indaptus Therapeutics, Inc. (INDP) | United States | $0.537B |